Skip to content
NASDAQ · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · SMALL CAP

CollPlant Biotechnologies Ltd. CLGN

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.4M
▲ 360.4% YoY
$-11.5M
$-9.4M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Our products are based on our recombinant human collagen (rhCollagen) that is produced in genetically engineered tobacco plants using our proprietary technology. In addition, we develop products in the field of medical aesthetics: Photocurable Dermal Filler, and 3D-bioprinted Breast Implants. Our regenerative 3D-bioprinted breast implants for regeneration of breast tissue are designed to address an unmet need derived from the estimated $3 billion global breast implant market.

Written from the business description in CollPlant Biotechnologies Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 26 March 2026. Every sentence was checked against that document before publication.

Growth

USD 2.4M
Revenue, FY2025 · full 8-year series below
Revenue $M Net income $M
FY2025 · Revenue 2.4 · Net income -11.5
10M20M-10M-20M
2018202120242025
Compound annual growth
+99.4%
−17.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −17.3% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−485 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -484.3% · Net -484.6%
-2000%-4000%
201820212025
ROE
FY2025 · ROE -117.6%
-100%-200%
201820212025
Three returns, three denominators.

Each USD of equity lost 118 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -9.4
-10M-20M
201820212025

Total assetsUSD 10.8M
EquityUSD 6.1M
CashUSD 5.6M
Current ratio2.53×

Equity funds 56% of total assets.

The 8-year record

8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
CLGN, 8-year financial record
Metric 20252024202320222021202020192018
Revenue $B0.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0
Income tax $B◌0.00.1◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0
EPS, diluted $−0.94−1.45−0.62−1.530.02−0.84−2.231.43
Dividend / sh $◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————
ROE %−117.6−79.5−23.2−43.71.0−134.8−234.8−118.0
Shares out B0.010.010.010.010.010.010.01◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 39 reconciliationsAUDITED

Reconciled in 8 of the 8 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 11 checks were skipped: EPS is not tagged before 2018. 11 checks were skipped: revenue is not tagged before 2018.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityOrthopedic, Prosthetic & Surgical Appliances & Supplies
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
Data on record since2017

Share this section

Download image